Welcome to our dedicated page for PLXP news (Ticker: PLXP), a resource for investors and traders seeking the latest updates and insights on PLXP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PLXP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PLXP's position in the market.
PLx Pharma Inc. (NASDAQ: PLXP) reported net sales of $2.1 million in Q1 2022, reflecting a 31% increase from Q4 2021, primarily driven by VAZALORE's strong promotion. The company experienced a GAAP net loss of $10.8 million, or ($0.39) per diluted share. Cash and equivalents stood at $52.5 million as of March 31, 2022. The first quarter saw a 44% gross margin and a decline in R&D expenses by 32%. Operating expenses rose significantly year-over-year but decreased sequentially by 11%. Overall, feedback on VAZALORE remains positive among consumers and healthcare professionals.
PLx Pharma Inc. (NASDAQ: PLXP) is set to release its 2022 first quarter financial results before U.S. market opening on May 13, 2022. The Company will also host a conference call at 8:30 AM ET to discuss performance and provide a business update. PLx’s VAZALORE liquid-filled aspirin capsules, available in 81 mg and 325 mg, utilize PLxGuard™ technology to enhance drug absorption and minimize stomach injury risks. This FDA-approved product aims to offer fast and reliable pain relief while retaining aspirin's lifesaving benefits.
PLx Pharma Inc. (NASDAQ: PLXP) reported total net sales of $8.2 million for 2021, primarily from its VAZALORE liquid-filled aspirin capsules. The fourth quarter saw net sales of $1.6 million, up from zero in Q4 2020. Despite a GAAP net loss of ($0.73) per diluted share, the company achieved a gross margin of 44%. Operating expenses rose to $21.6 million due to increased promotional activities. VAZALORE has quickly become the number three brand in the aspirin segment, reflecting strong initial market acceptance.
PLx Pharma Inc. (NASDAQ: PLXP) announced its participation in the 32nd Annual Healthcare Conference hosted by Oppenheimer & Co. on March 15, 2022. The event will feature presentations by Natasha Giordano, President and CEO, and Rita O’Connor, CFO, at 3:20 p.m. ET. The presentations will be available via webcast, with an archive for 30 days. PLx Pharma focuses on its patented PLxGuard™ technology to enhance drug absorption and mitigate stomach injury risks associated with certain medications.
PLx Pharma Inc. (NASDAQ: PLXP) announced it will release its 2021 fourth quarter financial results on March 11, 2022. The company specializes in drug delivery with its PLxGuard™ technology, which enhances drug absorption while minimizing stomach injury risks. Its lead products, VAZALORE 81 mg and VAZALORE 325 mg, are FDA-approved liquid-filled aspirin capsules designed for effective pain relief. A conference call for investors will be held at 8:30 a.m. ET on the release date to discuss performance and business updates.
PLx Pharma Inc. (NASDAQ: PLXP) announced the appointment of Janet M. Barth as the new Vice President of Investor Relations & Corporate Communications. This strategic move aims to enhance the company's investor relations program and strengthen stakeholder relationships, as stated by President & CEO Natasha Giordano. Barth brings nearly 30 years of experience in finance-driven investor communications from firms like Adams Respiratory Therapeutics and Bed Bath & Beyond. The company focuses on its PLxGuard™ technology and its lead product, VAZALORE, to enhance drug absorption and limit stomach injuries.
PLx Pharma Inc. (NASDAQ: PLXP) is set to participate in the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. Presenters will be Natasha Giordano, CEO, and Rita O’Connor, CFO. The company focuses on its PLxGuard™ technology, which enhances drug absorption and mitigates stomach injury risk. Its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg, are FDA-approved aspirin capsules offering targeted release. An archived version of the presentation will be available for 90 days post-event on their website.
PLx Pharma Inc. (NASDAQ: PLXP) reported net revenue of $6.6 million for Q3 2021, driven by the successful launch of VAZALORE, a liquid-filled aspirin product. The company has shipped to over 30,000 stores and received positive feedback from consumers and healthcare professionals. Despite this, the net loss was ($0.80) per share, an increase from the previous year. Total operating expenses rose to $12.6 million, largely due to marketing efforts. Cash and cash equivalents stood at $82.6 million as of September 30, 2021.
PLx Pharma has announced new findings regarding its VAZALORE 81 mg liquid-filled aspirin capsules, demonstrating rapid bioavailability and effective platelet inhibition. Data presented at the TCT 2021 meeting indicates that VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with its 325 mg counterpart. A crossover study showed significant absorption and platelet aggregation inhibition after a single dose. PLx Pharma emphasizes the potential for VAZALORE to enhance drug absorption while minimizing stomach injury risks. The company sees this as a vital addition to the clinical data supporting its FDA-approved products.
